Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238958 | 0.81 | LTA4H (0.66) | LMNAARCYP1A2PTGS1SLC6A2 | |
| SCHEMBL29498709 | 0.80 | PDGFRB (0.40) | ARMAOBBCHECHRNB2CHRNB4 | |
| SCHEMBL510570 | 0.80 | BCHE (0.49) | LMNAARCYP1A2PTGS1SLC6A2 | |
| SCHEMBL1767709 | 0.80 | NQO1 (0.54) | L3MBTL1MAPTRAB9ASMN1; SMN2LTA4H | |
| SCHEMBL1553970 | 0.80 | FFAR1 (0.45) | LMNAARCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL508861 | 0.79 | NPC1 (0.44) | LMNAARCYP1A2PTGS1SLC6A2 | |
| SCHEMBL30539400 | 0.78 | LTA4H (0.68) | LMNAARCYP1A2PTGS1SLC6A2 | |
| Tetradecane SCHEMBL28375680 | 0.78 | SLC6A2 (0.57) | LMNAARCYP1A2PTGS1SLC6A2 | |
| SCHEMBL276811 | 0.77 | LTA4H (0.38) | PTGS2SMN1; SMN2LTA4H | |
| SCHEMBL15923575 | 0.77 | LTA4H (0.66) | LMNAARCYP1A2PTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718264-B1 | BENZOCYCLOHEPTENE ACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-2718264-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| WO-2014022377-A1 | MEMBRANES AND COATINGS MADE FROM MIXTURES INCLUDING IONIC LIQUIDS HAVING SILICON-BONDED HYDROLYZABLE GROUPS | DOW CORNING CORPORATION (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| US-20030171345-A1 | 8Beta-substituted 11beta-aryl-estra-1,3,5,(10)-triene derivatives | SCHERING AG (DE) | 2003-09-11 | — | — | US | disclosed |
| WO-2003033516-A1 | 8β -SUBSTITUTED-11β -ARYL-ESTRA-1,3,5(10)-TRIENE DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | WO | disclosed |
| US-6319948-B2 | PREVENTION AND/OR MINIMIZATION OF SURGICAL ADHESION FORMATION BY ADMINISTERING CERTAIN SUBSTITUTED (5,6)-DIHYDRONAPHTHALENYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2001-11-20 | — | — | US | disclosed |
| US-20010003780-A1 | Retinoid antagonists and uses thereof | TRAMPOSCH KENNETH M (US) | 2001-06-14 | — | — | US | disclosed |
| WO-1998046228-A1 | RETINOID ANTAGONISTS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003780-A1 | Retinoid antagonists and uses thereof | RARA, RARB, RARG | LMNA 3210/4885AR 776/4885CYP1A2 1588/4885 |
| US-20030171345-A1 | 8Beta-substituted 11beta-aryl-estra-1,3,5,(10)-triene derivatives | CYP19A1, HSD17B11, GPER1 | LMNA 228/4885AR 72/4885CYP1A2 65/4885 |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | LMNA 3823/4885AR 498/4885CYP1A2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.